Tirzepatide qué es — what this medicine is and what the research shows

Why a dual-receptor medicine is different from earlier GLP-1 injections

Older GLP-1 medicines activate a single gut-hormone pathway. Tirzepatide goes further: it mimics both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), two hormones released after eating that signal fullness to the brain and slow the rate at which the stomach empties. Activating both pathways together appears to produce a stronger appetite-reducing effect than either alone.

The trial evidence reflects this. SURMOUNT-1 randomised 2,539 adults with obesity and no diabetes across several doses; at 15 mg the average weight reduction over 72 weeks reached around 20–21%. A later head-to-head study, SURMOUNT-5, directly compared tirzepatide with semaglutide 2.4 mg and found greater average weight loss with tirzepatide, a finding that informed NICE's appraisal of tirzepatide (TA1026), published in December 2024. These are clinical-trial figures; individual results differ, and what you experience depends on your starting weight, diet, activity and how your body responds.

If you want to read more about the full medicine profile, the tirzepatide overview page covers mechanism, storage and the licensed indications in more detail.

Who the UK licence covers, and what your BMI alone cannot tell you

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. For some ethnic backgrounds (including South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds) UK guidance applies thresholds that are 2.5 kg/m² lower.

BMI is a starting point, not the whole picture. A prescriber looks at your medical history, current medicines, and any conditions that might make tirzepatide unsuitable. It is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive, and it is not licensed for people under 18. A quick habit worth building now: check your current BMI using the NHS BMI calculator before your consultation, it takes under a minute and gives you a concrete number to discuss with the prescriber.

If your situation is a little more complex (for example, you are already on another treatment) the Mounjaro or tirzepatide page addresses some of the common switching and comparison questions.

Side effects, monitoring and what to watch for

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and occasionally vomiting. These tend to be most noticeable after starting or after a dose step-up, and for many people they ease within the first couple of weeks. Eating smaller portions, avoiding rich or fatty food, and staying well hydrated are practical steps that can help.

One side effect that warrants immediate medical attention is severe, persistent stomach pain that extends toward the back, with or without vomiting, this may indicate acute pancreatitis, which the MHRA Drug Safety Update published in January 2026 identified as a known, infrequently occurring but serious risk with GLP-1 medicines. Call 111 or go to A&E if that pattern of pain develops.

Tirzepatide holds Black Triangle (▼) status in the UK, which means the MHRA is still gathering post-market safety information. If you notice any unexpected effect, reporting it through the Yellow Card scheme at yellowcard.mhra.gov.uk contributes directly to that ongoing monitoring. For a thorough look at the side-effect profile by dose, the tirzepatide side effects page goes into further detail, and you can find dose-specific information for tirzepatide 10 and tirzepatide 30 on their respective pages.

Private prescription versus NHS: what the current picture looks like

NICE recommended tirzepatide on the NHS in December 2024, but rollout is phased and criteria are strict. As of mid-2026, NHS access requires a BMI of 40 or above plus four or more qualifying conditions; a second cohort covering BMI 35–39.9 with four or more conditions opened in June 2026, with further expansion planned. Many people who could benefit from the medicine do not yet meet NHS thresholds, or would rather not join a waiting list.

Private prescription is the alternative, and it is available now through a regulated pharmacy following a proper clinical assessment. The tirzepatide cost page sets out how private pricing is structured and what to look for in a legitimate quote. For a broader view of all available weight-loss treatment options, the treatment overview compares the licensed choices side by side.

At nume, every application is read and decided by a GPhC-registered Independent Prescriber, the same day it arrives. If tirzepatide is clinically suitable for you, treatment is dispatched the same day for free next-working-day delivery. When you feel ready to take that step, start your free consultation, there is no fee to apply and no obligation.